A Phase 1 interventional study of Febuxostat XR and Maalox Advance Regular Strength liquid in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-29.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.
The drug being tested in this study is called febuxostat extended-release (XR). Febuxostat XR is being tested to assess if antacids affect how the drug moves throughout the body. This study will look at lab safety and side effects in people who take febuxostat XR.
This cross-over study will enroll approximately 36 patients. Participants will be randomly assigned to one of four treatment sequences. All participants will receive the following study medications by the end of the study:
All participants will be administered one dose of one or both of the study medications on Day 1 of four separate study periods.
This single-centre trial will be conducted in the United States. The overall time to participate in this study is up to 84 days. Participants will make 5 visits to the clinic including four 4-day periods of confinement to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any participant who meets any of the following criteria will not qualify for entry into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid
Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid
Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid
Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid
Febuxostat extended-release (XR) capsules
Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
Cmax: Maximum Observed Plasma Concentration for Febuxostat
Time frame: Days 1 at multiple timepoints (up to 48 hours) post-dose
AUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat
Time frame: Days 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat
Time frame: Days 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Evaluation
Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG)
Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Participants took part in the study at 1 investigative site in United States from 23-Feb-15 to 04-May-15.
| Milestone | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 8 | 9 | 9 | 9 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Laboratory abnormality | 1 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Febuxostat | 883.58 ± 898.49 | 1075.08 ± 941.46 | 765.89 ± 480.2 | 1456.42 ± 875.39 |
| nanogram*hour per milliliter (ng*hr/mL) | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| AUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat | 4680.69 ± 2427.11 | 5877.99 ± 2888.9 | 4412.22 ± 1718.42 | 7316.21 ± 2811.1 |
| ng*hr/mL | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat | 5901 ± 2739.92 | 6999.9 ± 2912.71 | 4844.33 ± 1918.73 | 7697.85 ± 2732.63 |
| participants | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| TEAE | 2 | 1 | 3 | 2 |
| SAE | 0 | 0 | 0 | 0 |
| participants | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 |
| participants | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings | 0 | 0 | 0 | 0 |
| participants | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Evaluation | 0 | 0 | 0 | 0 |
| participants | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) | 0 | 0 | 0 | 0 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen A | — | 0/36 (0%) | 2/36 (5.6%) |
| Regimen B | — | 0/36 (0%) | 1/36 (2.8%) |
| Regimen C | — | 0/35 (0%) | 3/35 (8.6%) |
| Regimen D | — | 0/36 (0%) | 2/36 (5.6%) |
| Event | Regimen A | Regimen B | Regimen C | Regimen D |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/36 | 0/36 | 1/35 | 0/36 |
| NauseaGastrointestinal disorders | 0/36 | 0/36 | 1/35 | 0/36 |
| HeadacheNervous system disorders | 0/36 | 0/36 | 1/35 | 0/36 |
| Oral herpesInjury, poisoning and procedural complications | 1/36 | 0/36 | 0/35 | 0/36 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/36 | 0/36 | 0/35 | 1/36 |
| DizzinessNervous system disorders | 0/36 | 0/36 | 0/35 | 1/36 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/36 | 1/36 | 0/35 | 0/36 |
The safety set was defined as all participants who were enrolled and received at least 1 dose of study drug.
| Age, Continuous(years) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Mean | 37.8 ± 7.36 | 34.7 ± 13.42 | 31.7 ± 9.18 | 35.8 ± 11.38 | 35.0 ± 10.36 |
| Sex: Female, Male(Participants) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Female | 5 | 5 | 5 | 6 | 21 |
| Male | 4 | 4 | 4 | 3 | 15 |
| Race/Ethnicity, Customized(participants) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 4 | 5 | 17 |
| Not Hispanic or Latino | 4 | 6 | 5 | 4 | 19 |
| Race/Ethnicity, Customized(participants) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Black or African American | 1 | 2 | 4 | 3 | 10 |
| White | 8 | 6 | 5 | 5 | 24 |
| Multiracial | 0 | 1 | 0 | 1 | 2 |
| Smoking classification(participants) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Has never smoked | 8 | 9 | 8 | 8 | 33 |
| Is an ex-smoker | 1 | 0 | 1 | 1 | 3 |
| Alcohol classification(participants) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Has never drunk | 2 | 4 | 5 | 4 | 15 |
| Is a current drinker | 4 | 1 | 1 | 2 | 8 |
| Is an ex-drinker | 3 | 4 | 3 | 3 | 13 |
| Xanthine/caffeine consumption(participants) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Had xanthine/caffeine consumption | 5 | 5 | 3 | 5 | 18 |
| Had no xanthine/caffeine consumption | 4 | 4 | 6 | 4 | 18 |
| Female reproductive status(participants) | Regimen A, Then B, Then D, Then C | Regimen D, Then A, Then C, Then B | Regimen C, Then D, Then B, Then A | Regimen B, Then C, Then A, Then D | Total |
|---|---|---|---|---|---|
| Female of childbearing potential | 4 | 5 | 4 | 4 | 17 |
| Surgically sterile | 1 | 0 | 1 | 2 | 4 |
| N/A (participant is male) | 4 | 4 | 4 | 3 | 15 |
The record gives a start of Mar 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat